<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">jsms</journal-id><journal-title-group><journal-title xml:lang="ru">Journal of Siberian Medical Sciences</journal-title><trans-title-group xml:lang="en"><trans-title>Journal of Siberian Medical Sciences</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2542-1174</issn><publisher><publisher-name>Federal state budgetary educational institution of higher education "Novosibirsk state medical university" of  Ministry of Health of the Russian Federation (FSBEI HE NSMU MOH Russia)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.31549/2542-1174-2019-1-109-118</article-id><article-id custom-type="elpub" pub-id-type="custom">jsms-563</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group></article-categories><title-group><article-title>Ассоциация полиморфизмов промоторных участков генов MMP2, MMP3 и MMP9 с факторами сердечно-сосудистого риска у больных ревматоидным артритом</article-title><trans-title-group xml:lang="en"><trans-title>Association of polymorphisms in the promoter regions of MMP2, MMP3 and MMP9 genes with cardiovascular risk factors in patients with rheumatoid arthritis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Омельченко</surname><given-names>В. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Omelchenko</surname><given-names>V. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Омельченко Виталий Олегович — врач-ревматолог, врач-терапевт, младший научный сотрудник лаборатории патологии соединительной ткани.</p><p>630117, Новосибирск, ул. Тимакова, 2.</p></bio><bio xml:lang="en"><p>Omelchenko Vitaly Olegovich — Rheumatologist, Therapeutist, Junior  Researcher  of  the  Laboratory of Connective Tissue Pathology, Research Institute of Clinical and Experimental Lymphology.</p><p>2, Timakova Str, 630117, Novosibirsk.</p></bio><email xlink:type="simple">v.o.omelchenko@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Летягина</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Letyagina</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Летягина Елена Алексеевна — кандидат медицинских наук, врач-ревматолог, врач-терапевт, заведующий ревматологическим отделением клиники, старший научный сотрудник лаборатории патологии соединительной ткани.</p><p>630117, Новосибирск, ул. Тимакова, 2.</p></bio><bio xml:lang="en"><p>Letyagina Elena Alekseevna — Cand. Sci. (Med.), Rheumatologist, Head of the Rheumatology Department, Senior Researcher of the Laboratory of Connective Tissue Pathology, Research Institute of Clinical and Experimental Lymphology.</p><p>2, Timakova Str, 630117, Novosibirsk.</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шевченко</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Shevchenko</surname><given-names>А. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шевченко Алла Владимировна — доктор биологических наук, ведущий научный сотрудник лаборатории клинической иммуногенетики.</p><p>630117, Новосибирск, ул. Тимакова, 2.</p></bio><bio xml:lang="en"><p>Shevchenko Alla Vladimirovna — Cand. Sci. (Biol.), Leading Researcher of the Laboratory of Clinical Immunogenetics, Research Institute оf Clinical and Experimental Lymphology.</p><p>2, Timakova Str, 630117, Novosibirsk.</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Коненков</surname><given-names>В. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Konenkov</surname><given-names>V. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Коненков Владимир Иосифович — доктор медицинских наук, профессор, академик РАН, научный руководитель.</p><p>630117, Новосибирск, ул. Тимакова, 2.</p></bio><bio xml:lang="en"><p>Konenkov Vladimir Iosifovich — Dr. Sci. (Med.), Professor, Academician of the Russian Academy of Sciences, Scientific Director, Research Institute of Clinical and Experimental Lymphology.</p><p>2, Timakova Str, 630117, Novosibirsk.</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Поспелова</surname><given-names>Т. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Pospelova</surname><given-names>T. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Поспелова Татьяна Ивановна — доктор медицинских наук, профессор, заведующий кафедрой терапии, гематологии и трансфузиологии НГМУ; врач-гематолог, руководитель Городского гематологического центра.</p><p>Новосибирск.</p></bio><bio xml:lang="en"><p>Pospelova Tatyana Ivanovna — Dr. Sci. (Med.), Professor, Head of the Department of Therapy, Hematology and Transfusiology, Novosibirsk State Medical University; Hematologist, Head of the City Hematology Center.</p><p>Novosibirsk.</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Королев</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Korolev</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Королев Максим Александрович — кандидат медицинских наук, заведующий лабораторией патологии соединительной ткани.</p><p>630117, Новосибирск, ул. Тимакова, 2.</p></bio><bio xml:lang="en"><p>Korolev Maksim Aleksandrovich  — Cand. Sci. (Med.), Head of the Laboratory of Connective Tissue Pathology, Research Institute of Clinical and Experimental Lymphology.</p><p>2, Timakova Str, 630117, Novosibirsk.</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>НИИ клинической и экспериментальной лимфологии — филиал ФГБНУ «Федеральный исследовательский центр Институт цитологии и генетики СО РАН»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Research Institute of Clinical and Experimental Lymphology</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Новосибирский государственный медицинский университет Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Novosibirsk State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>25</day><month>07</month><year>2019</year></pub-date><volume>0</volume><issue>1</issue><fpage>109</fpage><lpage>118</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Омельченко В.О., Летягина Е.А., Шевченко А.В., Коненков В.И., Поспелова Т.И., Королев М.А., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Омельченко В.О., Летягина Е.А., Шевченко А.В., Коненков В.И., Поспелова Т.И., Королев М.А.</copyright-holder><copyright-holder xml:lang="en">Omelchenko V.O., Letyagina E.A., Shevchenko А.V., Konenkov V.I., Pospelova T.I., Korolev M.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://jsms.elpub.ru/jour/article/view/563">https://jsms.elpub.ru/jour/article/view/563</self-uri><abstract><p>С целью изучения ассоциации однонуклеотидных полиморфизмов промоторных участков генов MMP2, MMP3 и MMP9 с факторами сердечно-сосудистого риска и поражением каротидных артерий у больных ревматоидным артритом (РА) были обследованы 212 больных РА (181 женщина, 31 мужчина; средний возраст — 58.0 года) с умеренной и высокой активностью заболевания (средняя оценка по DAS28 — 4.96). В ходе исследования устанавливались традиционные и связанные с течением воспалительной артропатии факторы сердечно-сосудистого риска; проводилось генотипирование с определением однонуклеотидных полиморфизмов ММР3 5А-1171 6А (rs3025058), ММР9 С-1562Т (rs3918242), ММР2 С-1306Т (rs2438650). С помощью ультразвуковой доплерографии брахиоцефальных артерий выявляли атеросклеротические бляшки (АБ).</p><p>У больных с генотипом MMP9 -1562TT АБ встречались чаще, чем у носителей дикого аллеля С (71.4 % против 26.3 %, р = 0.022), и эта ассоциация сохранялась даже после корректировки по возрасту и полу. Генотип MMP2-1306TT встречался у 18.6 % больных с АБ в сравнении с 7.9 % у больных без бляшки (р = 0.025), но после коррекции по возрасту и полу данные различия нивелировались (р = 0.14).</p><p>Таким образом, выявлены отличия встречаемости различных генотипов MMP2 и MMP9 в зависимости от наличия АБ у больных РА, что свидетельствует о возможном влиянии этих полиморфизмов на поражение каротидных артерий и формирование предрасположенности к развитию сердечно-сосудистых событий.</p></abstract><trans-abstract xml:lang="en"><p>In order to study the association of single-nucleotide polymorphisms in the promoter regions of MMP2, MMP3 and MMP9 genes with cardiovascular risk factors and carotid artery lesions in patients with rheumatoid arthritis (RA) 212 patients with RA (181 women, 31 men; mean age — 58.0 years) with moderate and high disease activity were examined (average DAS28 score — 4.96). The study established traditional and associated with the course of inflammatory arthropathy cardiovascular risk factors; genotyping was carried out with the definition of single-nucleotide polymorphisms ММР3 5A-1171 6A (rs3025058), ММР9 С-1562Т (rs3918242), ММР2 С-1306Т (rs2438650). Atherosclerotic plaques were detected by ultrasound dopplerography of brachiocephalic arteries.</p><p>In patients with the MMP9 -1562TT genotype atherosclerotic plaques were more common than in carriers of wild-type allele C (71.4 % vs. 26.3 %, p = 0.022), and this association remained even after adjustment by age and sex. The MMP2 -1306TT genotype was found in 18.6 % of patients with AB compared to 7.9 % in patients without plaque (p = 0.025), but after correction by age and sex these differences were leveled (p = 0.14).</p><p>Thus, the differences in the occurrence of different MMP2 and MMP9 genotypes depending on the presence of AB in RA patients were revealed, which indicates the possible impact of these polymorphisms on the carotid arteries damage and the formation of a predisposition to the development of cardiovascular diseases.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>ревматоидный артрит</kwd><kwd>сердечно-сосудистые заболевания</kwd><kwd>факторы риска</kwd><kwd>атеросклероз</kwd><kwd>константные генетические маркеры</kwd><kwd>rs3025058</kwd><kwd>rs3918242</kwd><kwd>rs2438650</kwd></kwd-group><kwd-group xml:lang="en"><kwd>rheumatoid arthritis</kwd><kwd>cardiovascular  diseases</kwd><kwd>risk factors</kwd><kwd>atherosclerosis</kwd><kwd>constant genetic  markers</kwd><kwd>rs3025058</kwd><kwd>rs3918242</kwd><kwd>rs2438650</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Mahmoudi M. et al. New insights to the mechanisms underlying atherosclerosis in rheumatoid arthritis // Int. J. Rheum. Dis. 2017. Vol. 20 (3). P. 287–297.</mixed-citation><mixed-citation xml:lang="en">Mahmoudi M. et al. (2017). New insights to the mechanisms underlying atherosclerosis in rheumatoid arthritis. Int. J. Rheum. Dis., 20, 3, 287–297.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">DeCoux A., Lindsey M.L., Vilarreal F., Garcia R.A., Shulz R. Myocardial matrix metalloproteinase-2: inside out and upside down // J. Mol. Cell. Cardiol. 2014. Vol. 77. P. 64–72.</mixed-citation><mixed-citation xml:lang="en">DeCoux A., Lindsey M.L., Vilarreal F., Garcia R.A., Shulz R. (2014). Myocardial matrix metalloproteinase-2: inside out and upside down. J. Mol. Cell. Cardiol., 77, 64–72.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Khokha R., Murthy A., Weiss A. Metalloproteinases and their natural inhibitors in inflammation and immunity // Nat. Rev. Immunol. 2013. Vol. 13 (9). P. 649–665.</mixed-citation><mixed-citation xml:lang="en">Khokha R., Murthy A., Weiss A. (2013). Metalloproteinases and their natural inhibitors in inflammation and immunity. Nat. Rev. Immunol., 13, 9, 649–665.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Newby A.C. Metalloproteinases promote plaque rupture and myocardial infarction: A persuasive concept waiting for clinical translation // Matrix Biol. 2015. Vol. 44–46. P. 157–166.</mixed-citation><mixed-citation xml:lang="en">Newby A.C. (2015). Metalloproteinases promote plaque rupture and myocardial infarction: A persuasive concept waiting for clinical translation. Matrix Biol., 44–46, 157–166.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Price S.J., Greaves D.R., Watkins H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene. Role of Sp1 in allele-specific transcriptional regulation // J. Biol. Chem. 2001. Vol. 276 (10). P. 7549–7558.</mixed-citation><mixed-citation xml:lang="en">Price S.J., Greaves D.R., Watkins H. (2001). Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene. Role of Sp1 in allelespecific transcriptional regulation. J. Biol. Chem., 276, 10, 7549–7558.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Ye S. Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases // Matrix Biol. 2000. Vol. 19 (7). P. 623–629.</mixed-citation><mixed-citation xml:lang="en">Ye S. (2000). Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol., 19, 7, 623–629.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Bäck M., Ketelhuth D.F.J., Agewall S. Matrix metallo-proteinases in atherothrombosis // Prog. Cardiovasc. Dis. 2010. Vol. 52 (5). P. 410–428.</mixed-citation><mixed-citation xml:lang="en">Bäck M., Ketelhuth D.F.J., Agewall S. (2010). Matrix metalloproteinases in atherothrombosis. Prog. Cardiovasc. Dis., 52, 5, 410–428.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Маздорова Е.В., Рябиков А.Н., Максимов В.Н. и др. Связь каротидного атеросклероза с полиморфизмом 5А/6А гена матричной металлопротеиназы-3 // Бюл. СО РАМН. 2010. Т. 30, № 6. С. 46– 51.</mixed-citation><mixed-citation xml:lang="en">Mazdorova E.V., Ryabikov A.N.,  Maksimov  V.N.  et al. (2010). The relationship of carotid atherosclerosis with polymorphism of the 5A/6A gene of matrix metalloproteinase-3. Bull. Sib. Branch RAMS, 30, 6, 46–51. In Russ.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Шевченко В.В., Коненков В.И., Королев М.А., Убшаева Ю.Б., Прокофьев В.Ф. Полиморфизм генов матриксных металлопротеиназ ММР2, ММП3, ММП9 у женщин с ревматоидным артритом//Терапевт. арх. 2015. Т. 87, № 12. С. 36–40.</mixed-citation><mixed-citation xml:lang="en">Shevchenko V.V., Konenkov V.I., Korolev M.A., Ubshaeva Yu.B., Prokofiev  V.F.  (2015).  Polymorphism of matrix metalloproteinases genes MMP2, MMP3, MMP9 in women with rheumatoid arthritis. Therapeutic Archive, 87, 12, 36–40.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Yabluchanskiy A., Ma Y., Lyer R.P., Hall M.E. Matrix metalloproteinase-9: many shades of function in cardiovascular disease // Physiology. 2013. Vol. 28 (6). P. 391–403.</mixed-citation><mixed-citation xml:lang="en">Yabluchanskiy A., Ma Y., Lyer R.P., Hall M.E. (2013). Matrix metalloproteinase-9: many shades of function in cardiovascular disease. Physiology, 28, 6, 391–403.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
